Applications of Boc-O-Tert-Butyl-L-Serine Dicyclohexylamine Salt in Industrial Manufacturing

Boc-O-Tert-Butyl-L-Serine Dicyclohexylamine Salt plays a key role as a protected amino acid intermediate across multiple regulated segments of peptide synthesis and pharmaceutical manufacturing. Our in-house production and expertise support global downstream partners in maintaining strict quality, safety, and regulatory compliance in each application. Below, we highlight industry-specific use cases that rely on this material’s unique characteristics in their core workflows, from GMP drug substances to advanced chemical intermediates.

1. GMP Peptide Active Pharmaceutical Ingredient (API) Manufacturing

Boc-O-Tert-Butyl-L-Serine Dicyclohexylamine Salt functions as a highly pure protected-serine derivative that facilitates efficient stepwise elongation during solid-phase peptide synthesis (SPPS) and certain solution-phase protocols. Its chemical stability, along with ease of deprotection, makes it essential for pharmaceutical firms producing peptide APIs under GMP, particularly for sequences requiring site-specific serine residues with minimal racemization risk.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) Monographs for Peptide APIs
• US FDA 21 CFR Parts 210/211 for GMP Manufacturing
• USP General Chapter <797> for compounded sterile preparations (applicable to downstream peptide drug prep)

Typical usage ratio

• Used at 0.8–1.1 molar equivalents per serine position in peptide chains; the precise ratio depends on the coupling strategy, peptide length, and targeted purity profile for the final API batch.

Downstream process integration

• Material is introduced during the protected amino acid loading and chain elongation steps in automated peptide synthesizers or manual batch reactors. Post-coupling, selective Boc and tert-butyl deprotection steps follow as per validated drug master file (DMF) protocols.

Final product types

• Bulk GMP-peptides as APIs (e.g., GLP-1 analogues, vasopressin analogs, custom oligopeptides for research/clinical trials)
• Intermediates for injectable or oral peptide pharmaceuticals
• Kits for personalized peptide therapeutics
• Reference standards for peptide quality control

2. Research-Grade Custom Peptide Synthesis

CROs and biotech researchers employ Boc-O-Tert-Butyl-L-Serine Dicyclohexylamine Salt to build test peptides and analog libraries requiring orthogonally protected serine. Its minimal cross-reaction profile supports the development of new peptide antigen panels, labeled peptides, and sequence-optimized variants for structural biology, cell signaling, and proteomics projects in both academic and preclinical environments.

Industry compliance standards

• ISO 9001 Certified Quality Management Systems (for peptide synthesis labs)
• OECD Guidelines for Good Laboratory Practice (GLP) in non-clinical environments
• Material traceability per REACH Annex requirements for laboratory reagents
• NIH/NSF grant guidelines for chemical procurement (research use only, non-GMP)

Typical usage ratio

• Standard protocol utilizes equimolar ratios (1.0 mol equiv) per incorporated serine site; adjustments are made for resin loading density, desired peptide scale, and C-terminal modification protocols.

Downstream process integration

• Employed during Fmoc/Boc hybrid SPPS or solution-phase assembly as the protected serine component. Peptide cleavage from the resin and final global deprotection usually occur post all coupling cycles, followed by preparative HPLC purification in accordance with lab SOPs.

Final product types

• Peptide antigen standards for immunoassays (e.g., ELISA calibration peptides)
• Stable isotope-labeled or fluorescent peptide probes
• Epitope-mapping peptide arrays
• In vitro bioactivity screening peptides

3. Oligopeptide Cosmetic Ingredient Formulations

The ingredient finds regulated use as a protected serine building block in the synthesis of cosmetic-grade oligopeptides for anti-aging, moisturizing, and skin-barrier-enhancing product lines. These active peptides require high raw material purity and reproducibility to satisfy cosmetic ingredient listing rules in regions such as the EU and Japan, where INCI designation and traceable production records are mandatory for downstream marketing.

Industry compliance standards

• EU Cosmetics Regulation (EC) No. 1223/2009
• Japan Standards for Cosmetic Ingredients (JSQI)
• ISO 22716: Cosmetics—Good Manufacturing Practices (GMP)
• INCI (International Nomenclature of Cosmetic Ingredients) registration

Typical usage ratio

• Formulators select 0.95–1.2 molar equivalents per serine position to maximize yield and minimize by-products in solution-phase peptide synthesis, adapting to hydrolysis sensitivity and required peptide purity for leave-on versus rinse-off cosmetic formulations.

Downstream process integration

• Introduced at the serine coupling stage of oligopeptide synthesis; subsequent deprotection and purification operations yield an additive-grade peptide powder, which undergoes characterization and quality release per ISO 22716 protocols before cosmetic formulation or export.

Final product types

• Short-sequence cosmetic peptides (e.g., tripeptides, hexapeptides)
• Peptide complexes for anti-wrinkle and firming creams
• Moisturizing peptide actives for serums and gels
• Bioactive peptide concentrates for skin repair masks

4. Protected Amino Acid Intermediates for Fine Chemical Synthesis

Chemical companies active in advanced material science and fine intermediate production utilize this product as a protected serine source for functionalizing complex molecules, synthesizing specialty esters, or providing orthogonal protection in multi-step heterocyclic or chiral intermediate routes. Consistent physical quality and impurity profiles support reliable scale-up in industrial kilo-lab and pilot-plant environments where intermediate integrity directly impacts downstream process safety and purity.

Industry compliance standards

• ISO 9001:2015 Quality Management for Chemical Process Industries
• Responsible Care® Global Charter (for environmental and product stewardship)
• REACH Registration (EU chemicals, intermediates)
• National Fire Protection Association (NFPA) standards for safe handling of organic fine chemicals

Typical usage ratio

• Typically charged at 1.0–1.2 mol equivalents for functional group installation, with variation depending on desired yield, scale, and the number of deprotection/derivatization cycles in the chemical scheme.

Downstream process integration

• Dosed at the initial protection step and maintained through multiple reaction stages in the synthesis of chiral auxiliaries or advanced intermediates. Subsequent selective deprotection and further transformation integrate with downstream partner protocols for specialty product manufacture.

Final product types

• Chiral building blocks for active material synthesis
• Protected amino acid derivatives for life science research reagents
• Enantiopure intermediates for pharmaceutical R&D
• Advanced synthetic intermediates for specialty organic compounds

5. Injectable Bulk Peptide Excipient Processing

Boc-O-Tert-Butyl-L-Serine Dicyclohexylamine Salt supports peptide manufacturers producing injectable peptide excipients where endotoxin levels, residual solvent profile, and elemental impurities are subject to injectable-grade specifications. High batch-to-batch consistency in the protected serine component optimizes excipient purity and manufacturing efficiency for both sterile and non-sterile injectable formulations.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) for Excipients
• USP–NF General Chapter <1079> on Good Storage & Shipping of Peptide Excipients
• US FDA cGMP (21 CFR Part 211)
• ICH Q3D for Elemental Impurities Control

Typical usage ratio

• Applied at 0.9–1.05 molar equivalents relative to target peptide sequence length, optimized according to the excipient’s solubility, biocompatibility, and regulatory requirements for parenteral administration.

Downstream process integration

• Fed into the protected amino acid addition and coupling steps for multi-gram scale peptide excipient synthesis. Downstream purification, lyophilization, and bulk sterilization processes follow per excipient-grade release standards prior to end-filling and distribution.

Final product types

• Pharmaceutical excipient peptides for injection (stabilizers, diluents)
• Peptide-based drug carrier systems
• Bulk injectable lyophilized peptide powders
• Pre-mixed parenteral peptide excipient solutions